Skip to content
Peptigraph home

Ipamorelin

GHRP (ghrelin receptor agonist). Ipamorelin is not FDA approved for any use.

Also called:ipaipam
Medically reviewed by Juan Pablo Frías, MD · · DisclosureUpdated Strongest evidence: Human RCT evidence, 4 of 4
StatusNot FDA approved · research chemicalProhibited by WADA (S2.2.4)Full legal history

Key facts

Class
GHRP (ghrelin receptor agonist)
Also called
ipa, ipam
Vial sizes sold
2 mg, 5 mg, 10 mg
Community-reported sizes
Half-life
2 hours terminal half-life
intravenous infusion (15 min), in people · Pharmaceutical research 1999, PMID 10496658
FDA status
Not approved
research chemical
WADA
Prohibited (S2.2.4)
In and out of competition
Everything on Ipamorelin

Ipamorelin guides

Vial and dose sizes

Evidence at a glance

Human and animal counts are PubMed records from our evidence ledger (search counts, not studies we reviewed). The grade is the strongest design among the studies we summarised for that goal: a human randomized trial outweighs any number of animal studies.

Ipamorelin: studies by condition
ConditionHuman studiesAnimal studiesStudies we summarisedEvidence grade
Menopause000No graded study for this goal
Muscle growth114Animal evidence, 2 of 4Growth hormone & IGF research 2001, PMID 11735244

Grades follow our evidence scale. Summarised studies come from our evidence file, each quote checked against the abstract or label.

A selective growth hormone secretagogue

Ipamorelin was described as the first GHRP-receptor agonist with a selectivity for GH release similar to that of GHRH.[11]

In the animal work that introduced it (rat and swine), ipamorelin did not release ACTH or cortisol at levels significantly different from GHRH stimulation.[11]

In human volunteers, an intravenous infusion produced a single episode of GH release, peaking at 0.67 hours and declining to negligible levels.[6]

Human data: one volunteer study and one surgical trial

The one randomized efficacy trial, in bowel-resection patients, found no significant differences from placebo.[5]

In the same trial, ipamorelin at 0.03 mg/kg twice daily for up to 7 days was well tolerated.[5]

The bone and growth results are from rats: ipamorelin and GH-releasing peptide-6 increased body weight and bone mineral content in adult female rats.[12]

Regulatory path

Drugs@FDA has no ipamorelin product.[2]

FDA's significant-safety-risk table lists ipamorelin acetate for 503B outsourcing, dated September 29, 2023.[3]

WADA's list names ipamorelin among growth hormone secretagogues and their mimetics.[1]

Compared with

Common stacks

Ipamorelin is often sold pre-mixed or combined with other peptides. No controlled study has tested these combinations; the pages below cover the math and what each part has been studied for.

Common questions

Is Ipamorelin FDA approved?

No. Ipamorelin is not FDA approved for any use.

Is Ipamorelin banned in sport?

Yes. Prohibited by WADA (S2.2.4), so it is prohibited at all times for tested athletes.

How much water goes in a 10 mg vial?

That choice only changes the concentration. With 2 mL, the vial is 5 mg/mL. The calculator converts any amount to syringe units. It does the math only and does not suggest a dose.

What is ipamorelin?

A growth hormone-releasing peptide receptor agonist, described as the first with GH-release selectivity similar to GHRH.[11]

Is ipamorelin for men?

The human efficacy trial cited studied ipamorelin for postoperative ileus after abdominal surgery; no study tested it as a treatment for men.[5]

What do studies of ipamorelin show?

The human efficacy trial found no significant benefit over placebo on its main measure.[5]

Sources

  1. 1World Anti-Doping Code International Standard Prohibited List 2026World Anti-Doping Agency · 2026wada-ama.orgAccessed 2 Oct 2026
  2. 2United States: No FDA-approved product found: Drugs@FDA (openFDA) search for active ingredient "ipamorelin" returned no matches on 2 Oct 2026.U.S. Food and Drug Administration · 2026api.fda.govAccessed 2 Oct 2026
  3. 3US compounding: Ipamorelin acetate is in FDA's 503B category 2 (added 29 September 2023).U.S. Food and Drug Administration · 2026fda.govAccessed 2 Oct 2026
  4. 4FDA warning letters to five research-peptide sellersFDA warning letter (NuScience Peptides; 1 of 5) · 2026fda.govAccessed 2 Oct 2026
  5. 5Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients.International journal of colorectal disease · 2014PMID 25331030Accessed 2 Oct 2026
  6. 6Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers.Pharmaceutical research · 1999PMID 10496658Accessed 2 Oct 2026
  7. 7PubMed search: ipamorelin[tiab] (50 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  8. 8PubMed search: ipamorelin[tiab] AND (half-life[tiab] OR pharmacokinetic*[tiab]) (4 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  9. 9The growth hormone secretagogue ipamorelin counteracts glucocorticoid-induced decrease in bone formation of adult rats.Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society · 2001PMID 11735244Accessed 2 Oct 2026
  10. 10PubMed search: ipamorelin[tiab] AND (adverse[tiab] OR "side effect*"[tiab] OR safety[tiab] OR tolerab*[tiab] OR toxicity[tiab] OR "case report"[pt]) (11 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 11 Oct 2026
  11. 11Ipamorelin, the first selective growth hormone secretagogue.European journal of endocrinology · 1998PMID 9849822Accessed 2 Oct 2026
  12. 12The GH secretagogues ipamorelin and GH-releasing peptide-6 increase bone mineral content in adult female rats.The Journal of endocrinology · 2000PMID 10828840Accessed 2 Oct 2026

Found an error? Report a correction.